Anticoagualtion and antiplatelets

Slides:



Advertisements
Similar presentations
Chapter 19 Hematologic Products.
Advertisements

Anticoagulant, Antiplatelet, and Thrombolytic Drugs
Platelet Aggregation Inhibitors
ANAESTHESIA AND ANTICOAGULANTS
Regional Anesthetics and Anticoagulation Marie Sankaran Raval M.D. Boston Medical Center Department of Anesthesiology Nina Zachariah M.D.
Vascular Pharmacology
Anti-platelet drugs Dr. Ishfaq Bukhari Dec
Antiplatelet Drugs (Anti-thrombotics)
Manufacturer: Daiichi Sankyo FDA Approval Date: 01/08/2015
Dr. Ishfaq Bukhari.  In healthy vasculature, circulating platelets are maintained in an inactive state by nitric oxide (NO) and prostacyclinre (PGI2)leased.
ANTICOAGULANT BY :DR ISRAA OMAR.
NURS 1950 Pharmacology I 1.  Objective 1: identify general reasons anticoagulants are given 2.
Drugs used in coagulation disorders By S.Bohlooli, Ph.D.
BY :DR. ISRAA OMAR.  It is initiated concomitantly with coagulation cascade, resulting in the formation of active plasmin,which digest fibrin.  The.
Anticoagulant, Antiplatelet, and Thrombolytic Drugs
ANTICOAGULANT, THROMBOLYTICS & ANTIPLATELET DRUGS.
Total Joint Replacement
Ticlopidine (Ticlid™) and Clopidogrel (Plavix™) Benedict R. Lucchesi, M.D., Ph.D. Department of Pharmacology University of Michigan Medical School.
Anticoagulants 1. Parenteral Anticoagulants e.g. heparin
Drugs for Coagulation disorders. There are a number of different categories of drugs which modify the coagulation process: I. Anticoagulants II. Antiplatelet.
Thrombolytic drugs BY :DR. ISRAA OMAR.
Dr. Mahmoud H. Taleb1 Pharmacology II Lecture 1 Pharmacology of Blood Dr. Mahmoud H. Taleb Assistant Professor of Pharmacology and Toxicology Head of Department.
ANTIPLATELET DRUGS.
Developed by: Dawn Johnson, RN, MSN, Ed.  Internally and externally  Prevent bleeding from wounds which could lead to shock or even death.
Drugs Used to Treat Thromboembolic Disorders Chapter 27 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
ASPIRIN ↓ Cox inhibition ↓ (PROSTACYCLIN) PGI 2 & TXA 2 (THROMBOXANE) LOW DOSE ASPIRIN.
Fibrinolytics, anticoagulants and antiplatelets
ANTIPLATELET DRUGS Learning objectives By the end of this lecture, students should be able to: - describe different classes of anti-platelet drugs and.
ANTIPLATELETES AGENTS BY :DR. ISRAA OMAR. The role of platelets Platelets play a critical role in thromboembolic disease like ischemic heart disease and.
ANTIPLATELETES AGENTS
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to to describe different classes of anti-platelet.
Antiplatelet drugs Dr.V.V.Gouripur. Antiplatelet drug An antiplatelet drug is a member of a class of drugs that decreases platelet aggregation and inhibits.
Blood coagulation is a complex process that involves vasoconstriction, platelet clumping or aggregation, and a cascade of clotting factors produced in.
Agents Affecting Blood Clotting
Dr. Laila M. Matalqah Ph.D. Pharmacology
Coagulation Modifier Agents Lilley Pharmacology Text: Chapter 26 Original Text modified by: Anita A. Kovalsky, R.N., M.N.Ed. Professor of Nursing Original.
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to To describe the role of platelets in.
Prof. Abdulrahman Almotrefi
Anticoagulants Course: Pharmacology I Course Code: PHR 213 Course Instructor: Sabiha Chowdhury Lecturer Department of Pharmacy BRAC University.
Drugs Used in Coagulation Disorders
Anticoagulant, Antiplatelet, and Thrombolytic Drugs.
II. Antiplatelet Drugs.
Chapter 23 Thrombo-Embolic diseases
23 Anticoagulants.
Anticoagulants, Antiplatelets, and Thrombolytics
ANTIPLATELETS AND ANTICOAGULANTS
Thrombus VS. Embolus A clot that adheres to a vessel wall is called a thrombus, whereas an intravascular clot that floats in the blood is termed an embolus.
Antiplatelets Anticoagulants Drugs Thrombolytics
By: Dr. Nalaka Gunawansa
Antithrombotic drugs Fibrinolytics
Anticoagulant therapy
Anticoagulation in Atrial Fibrillation
Med Chem Tutoring for Anticoagulants, Antiplatelets, and Thrombolytics
The normal haemostasis process involves three stages: 1
Use of NOACs is contraindicated for AF patients with mechanical prosthetic valves or moderate- severe mitral stenosis (usually of rheumatic origin). Although.
داروهای موثر بر سیستم قلبی وعروقی جدید در ایران
Mandeep Singh, MD, MPH, Deepak L. Bhatt, MD, MPH, Gregg W
ANTICOAGULANTS Dr. A. Shyam Sundar. M.Pharm., Ph.D,
Paul A. Gurbel, and Udaya S. Tantry JCHF 2014;2:1-14
23 Anticoagulants.
Drugs Affecting Blood.
Anticoagulant Drugs Dr. : Asmaa Fady MD., MSC, M.B, B.Ch
Prof. Abdulrahman Almotrefi
Anti-Platelet Drugs Dr. A. Shyam Sundar. M.Pharm., Ph.D,
Antiplatelet Drugs Dr. : Asmaa Fady MD., MSC, M.B, B.Ch
Section B: Science update
FIBRINOLYTIC DRUGS VIJAYA LECHIMI RAJ.
Presentation transcript:

Anticoagualtion and antiplatelets Hashem m. mansour

Introduction Thrombosis, the formation of an unwanted clot within a blood vessel. Thrombotic disorders include acute myocardial infarction (MI), deep vein thrombosis (DVT), pulmonary embolism (PE), and acute ischemic stroke. These conditions are treated with drugs such as anticoagulants and fibrinolytics.

Thrombosis versus embolism A clot that adheres to a vessel wall is called a “thrombus,” whereas an intravascular clot that floats in the blood is termed an “embolus. Arterial thrombosis usually consists of a platelet-rich clot. In contrast, venous thrombosis is triggered by blood stasis or inappropriate activation of the coagulation cascade.

D. Platelet aggregation E. Formation of a clot F. Fibrinolysis Thrombus formation A. Tissue injury. B. Platelet adhesion C. Platelet activation D. Platelet aggregation E. Formation of a clot F. Fibrinolysis

Platelet aggregation inhibitors The platelet aggregation inhibitors inhibit 1) cyclooxygenase-1 (COX-1) or 2)block GP IIb/IIIa or 3)ADP receptors, thereby interfering with the signals that promote platelet aggregation.

Aspirin Mechanism of action: Aspirin inhibits thromboxane A2 synthesis irreversibly by inhibiting cycloxygenase enzyme. Thromboxane A2 promotes the aggregation process that is essential for the rapid formation of a hemostatic plug.

Aspirin Effect The inhibitory effect is rapid, and aspirin-induced suppression of platelet aggregation last for the life of the platelet ( 7 to 10 days). Aspirin is the only antiplatelet agent that irreversibly inhibits platelet function

Therapeutic use Aspirin is used in the prophylactic treatment of transient cerebral ischemia Reduce the incidence of recurrent MI, and to decrease mortality in the setting of primary and secondary prevention of MI.

Adverse effects Increased incidence of hemorrhagic stroke and gastrointestinal (GI) bleeding. Bronchospasm . Renal damage. Angioedema. Hepatotxicity. Nonsteroidal anti-inflammatory drugs, such as ibuprofen, if taken within the 2 hours prior to aspirin, can antagonize platelet inhibition by aspirin.

Ticlopidine, clopidogrel, prasugrel, and ticagrelor Mechanism of action: These drugs inhibit the binding of ADP to its receptors on platelets and, thereby, inhibit the activation of the GP IIb/IIIa receptors required for platelets to bind to fibrinogen and to each other. Ticagrelor binds to the P2Y12 ADP receptor in a reversible manner.

The maximum inhibition of platelet aggregation is achieved in Max effects The maximum inhibition of platelet aggregation is achieved in 1 to 3 hours with ticagrelor. 2 to 4 hours with prasugrel. 3 to 4 days with ticlopidine. 3 to 5 days with clopidogrel.

Therapeutic use Prophylaxis of thrombotic events in acute coronary syndromes and percutaneous coronary intervention (PCI). Ticlopidine is indicated for the prevention of transient ischemic attacks (TIA) and strokes in patients with a prior cerebral thrombotic event.

They undergo hepatic metabolism. Elimination renal and fecal routes. Pharmacokinetics They undergo hepatic metabolism. Elimination renal and fecal routes. Drugs that inhibit CYP 2C19, such as omeprazole and esomeprazole, should not be administered concurrently with clopidogrel.

These agents cause prolonged bleeding. Adverse effects These agents cause prolonged bleeding. Agranulocytosis, thrombotic thrombocytopenic purpura (TTP), and aplastic anemia. Prasugrel is contraindicated in patients with history of TIA or stroke.

Anticoagulants Heparin and low molecular weight heparins Mechanism of action: Heparin anticoagulant effect is due to antithrombin III, with the subsequent rapid inactivation of coagulation factors. LMWHs complex with antithrombin III and inactivate factor Xa.

Therapeutic use Treatment of acute venous thromboembolism (DVT or PE). Prophylaxis of postoperative venous thrombosis in patients undergoing surgery The anticoagulants of choice for treating pregnant women. LMWHs do not require the same intense monitoring as heparin.

Heparin administered subcutaneously or intravenously. Pharmacokinetics Heparin administered subcutaneously or intravenously. The LMWHs are administered subcutaneously. In renally impaired, pregnant, and obese patients, monitoring of factor Xa levels is recommended with LMWHs.

Adverse effects Bleeding. Excessive bleeding managed by discontinuing the drug or with protamine sulfate. chills, fever, urticaria, and anaphylactic shock. Heparin-induced thrombocytopenia (HIT) is a serious condition, in which circulating blood contains an abnormally low number of platelets

Adverse effects Heparin therapy should be discontinued when patients develop HIT or show severe thrombocytopenia. osteoporosis Heparin and LMWHs are contraindicated in patients who have bleeding disorders, or who have had recent surgery of the brain, eye, or spinal cord.

Rivaroxaban and apixaban Mechanism of action: Rivaroxaban and apixaban are oral inhibitors of factor Xa. Therapeutic use: Rivaroxaban is approved for treatment and prevention of DVT and PE and for the prevention of stroke in nonvalvular atrial fibrillation. Apixaban is used for stroke prevention in nonvalvular atrial fibrillation.

Bleeding is the most serious adverse effect. Adverse effects Bleeding is the most serious adverse effect. As both drugs are eliminated renally. neither drug should be used in severe renal dysfunction (creatinine clearance less than 15 mL/min). Abrupt discontinuation of these agents should be avoided.

It work by antagonizing the effects of Vit K Warfarin Mechanism of action: Factors II, VII, IX, and X require vitamin K as a cofactor for their synthesis by the liver. It work by antagonizing the effects of Vit K

Warfarin con. The anticoagulant effects of warfarin may be delayed for 72 to 96 hours. The anticoagulant effects of warfarin can be overcome by the administration of vitamin K. Reversal following administration of vitamin K takes approximately 24 hours.

Therapeutic use Warfarin is used in the prevention and treatment of DVT and PE, stroke prevention, Stroke prevention in the setting of atrial fibrillation and/or prosthetic heart valves and antiphospholipid syndrome.

Warfarin is rapidly absorbed after oral administration Pharmacokinetics Warfarin is rapidly absorbed after oral administration Readily crosses the placental barrier. Metabolized by liver. Excreted in urine and feces. Warfarin has numerous drug interactions.

Adverse effects The principal adverse effect of warfarin is hemorrhage, Skin lesions and necrosis are rare complications of warfarin therapy. Purple toe syndrome, a rare, painful, discoloration of the toe caused by cholesterol emboli. Warfarin is teratogenic and should never be used during pregnancy.

Recent CNS and eye surgery Threatened abortion and eclampsia Contraindication Bleeding pregnancy Recent CNS and eye surgery Threatened abortion and eclampsia Spinal puncture Malignant hypertension Hypersensitivity Pt with high level of non compliance

D X Apixaban Mifepristone Drug interaction Phenobarbital Prasugrel Protamine Sulfamethoxazole Testosterone Vit k Apixaban Mifepristone

Drug interaction D Allopurinol Amiodarone Abciximab Azithromycin Antithrombin III Bezafibrate Carbamazepine Cefazoline metronidazole Cefpodoxime Ceftriaxone Cefuroxime Ciprofloxacin Clarithromycin Clotrimazole Erythromycine Itraconazole Levothyroxine

Implication in physiotherapy Anticoagulants and antiplatelet are very important drugs in medicine. Also they are dangerous drugs due to their side effects especially bleeding. Most of these drugs need continuous follow up, monitoring and education. P.T should be aware for the above mentioned issues.

Implication in physiotherapy Before starting Physio-Therapy session you should ask the patient about the last follow up especially for those on warfarin. Elevated INR may expose patient to bleeding during exercise. The exercise should be done gently, since extraneous exercise increase the risk of bleeding such as ecchymosis and petechia. Be aware of any sharp material near the patient during exercise.

Implication in physiotherapy You can educate the patient about the proper way of using these drugs. Sterile pads should be available to cover any accidental injury. Remember these drugs are used in serious cases as stroke, cardiac, or pulmonary disease, so you must take this into your consideration.